Table 1.
Baseline characteristics of UGT1A1*6 and UGT1A1*28
| Characteristics | UGT1A1*6 | P | UGT1A1*28 | P | ||
| WT (n=64) | HM (n=43) | WT (n=81) | HM (n=26) | |||
| *WT: wild-type; HM: heterozygous mutation; M: homozygous mutation; CRC: colorectal cancer. | ||||||
| Gender | 0.124 | 0.129 | ||||
| Male | 29 (45.31%) | 26 (60.47%) | 45 (55.56%) | 10 (38.46%) | ||
| Female | 35 (54.69%) | 17 (39.53%) | 36 (44.44%) | 16 (61.54%) | ||
| Smoking history | 0.587 | 0.489 | ||||
| Yes | 22 (34.38%) | 17 (39.53%) | 31 (38.27%) | 8 (30.77%) | ||
| No | 42 (65.62%) | 26 (60.47%) | 50 (61.73%) | 18 (69.23%) | ||
| Hyperbilirubinemia | < 0.001 | 0.060 | ||||
| Yes | 4 (6.25%) | 14 (32.56%) | 10 (12.35%) | 8 (30.77%) | ||
| No | 60 (93.75%) | 29 (67.44%) | 71 (87.65%) | 18 (69.23%) | ||
| SLCO1B1 | 0.742 | 0.260 | ||||
| WT | 5 (7.81%) | 5 (11.63%) | 6 (7.41%) | 4 (15.38%) | ||
| HM | 24 (37.50%) | 17 (39.53%) | 34 (41.98%) | 7 (26.92%) | ||
| M | 35 (54.69%) | 21 (48.84%) | 41 (50.62%) | 15 (57.69%) | ||
| CRC | 0.549 | 0.986 | ||||
| Yes | 38 (59.38%) | 28 (65.12%) | 50 (61.73%) | 16 (61.54%) | ||
| No | 26 (40.62%) | 15 (34.88%) | 31 (38.27%) | 10 (38.46%) | ||
| Treatment lines | 0.830 | 0.635 | ||||
| First-line | 26 (40.62%) | 20 (46.51%) | 34 (41.98%) | 12 (46.15%) | ||
| Second-line | 26 (40.62%) | 16 (37.21%) | 31 (38.27%) | 11 (42.31%) | ||
| Third-line | 12 (18.75%) | 7 (16.28%) | 16 (19.75%) | 3 (11.54%) | ||
| Regimen | 0.682 | 0.191 | ||||
| Single | 14 (21.88%) | 8 (18.60%) | 19 (23.46%) | 3 (11.54%) | ||
| Combined | 50 (78.12%) | 35 (81.40%) | 62 (76.54%) | 23 (88.46%) | ||
| Dose decrease | 0.043 | 0.619 | ||||
| ≤10% | 49 (76.56%) | 25 (58.14%) | 55 (67.90%) | 19 (73.08%) | ||
| > 10% | 15 (23.44%) | 18 (41.86%) | 26 (32.10%) | 7 (26.92%) | ||
| Dose decrease | 0.003 | 0.321 | ||||
| Yes | 35 (54.69%) | 11 (25.58%) | 37 (45.68%) | 9 (34.62%) | ||
| No | 29 (45.31%) | 32 (74.42%) | 44 (54.32%) | 17 (65.38%) | ||